Labcorp 以 2.375 亿美元收购 BioReference Health 资产，专注于美国实验室服务（不包括纽约州和新泽西州），以增强服务并简化实验室业务。 Labcorp acquires BioReference Health assets for $237.5M, focusing on US lab services, excluding NY & NJ, to enhance services and streamline lab business.

Labcorp 将以 2.375 亿美元的价格收购 BioReference Health 的精选资产，重点关注美国（纽约州和新泽西州除外）的临床诊断和生殖/女性健康。 Labcorp to acquire select assets of BioReference Health in a $237.5M deal, focusing on clinical diagnostics and reproductive/women's health across the US excluding NY and NJ. 此举旨在增强 Labcorp 的实验室服务网络，增加患者获得其服务的机会，并简化 OPKO Health 的实验室服务业务。 This is aimed at enhancing Labcorp's lab services network, increasing patient access to its services, and streamlining OPKO Health's laboratory services business. 该交易尚待监管部门批准，预计将于 2024 年下半年完成。 The transaction is subject to regulatory approvals and expected to close in the second half of 2024.